Top Markets
Coin of the day
Novo Nordisk A/S Novo Nordisk A/S

Novo Nordisk A/S

NOVO-B
Rangering i aksjer #107
Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the... Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
Aksjekurs
$41.14
Sist synkronisert: 2026-09-21
Markedsverdi
$182.76B
Endring (1 dag)
-7.78%
Endring (1 år)
-32.24%
Land
DK
Handel Novo Nordisk A/S (NOVO-B)

Kategori

Inntekter for Novo Nordisk A/S (NOVO-B)
Inntekter i Jun 2026 TTM: $52.30B
Ifølge de nyeste økonomiske rapportene til Novo Nordisk A/S er selskapets nåværende inntekter (TTM) $52.30B. I 2024 hadde selskapet inntekter på $40.52B en økning sammenlignet med inntektene i 2023, som var $34.39B. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Novo Nordisk A/S fra 2000 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
2026 (TTM) $52.30B 12.04%
2025 $46.68B 15.22%
2024 $40.52B 17.82%
2023 $34.39B 35.02%
2022 $25.47B 18.29%
2021 $21.53B 3.33%
2020 $20.84B 13.79%
2019 $18.31B 6.63%
2018 $17.17B -4.59%
2017 $18.00B 13.46%
2016 $15.86B 0.88%
2015 $15.73B 8.89%
2014 $14.44B -6.28%
2013 $15.41B 11.69%
2012 $13.80B 19.42%
2011 $11.55B 6.01%
2010 $10.90B 10.52%
2009 $9.86B 15.53%
2008 $8.54B 3.65%
2007 $8.24B 20.44%
2006 $6.84B 28.15%
2005 $5.34B -0.14%
2004 $5.34B 18.51%
2003 $4.51B 27.01%
2002 $3.55B 25.45%
2001 $2.83B 9.05%
2000 $2.60B 0.00%
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$79.67B 52.31%
US
$97.93B 87.23%
US
$64.39B 23.10%
US
$77.52B 48.21%
CH
$66.40B 26.95%
US